Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Esophageal Neoplasms

Carcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Esophageal Diseases

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Carboplatin

Cisplatin

Immunomodulating Agents

Nedaplatin

Tubulin Modulators

Antimitotic Agents

1. camrelizumab 200mg intravenous drip d1q3w
2. Paclitaxel: 150mg/m2 d1 q3w
3. Platinum: Cisplatin, carboplatin, nedaplatin and other platinum drugs
4. Radiotherapy dose: 5040cGy/28f radiotherapy efficacy evaluation after 2-3 cycles of chemotherapy PR/SD received local radiotherapy.

camrelizumab

Paclitaxel drugs

Cisplatin, carboplatin, nedaplatin and other platinum drugs

Platinum drug

Radiation

Jiancheng Li, Doctor

This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Prospective Single-arm, Exploratory, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemoradiotherapy in the Treatment of Advanced First-line Esophageal Phosphorous Carcinoma

ORR is determined using RECIST v1.1, defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment.

Defined as the time from the enrollment to death from any cause

It is defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first.

Fujian Cancer Hospital

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Anti-Inflammatory Agents

Antiemetics

Neuroprotective Agents

Gastrointestinal Agents

Docetaxel

Hormones

Prednisone

Prednisolone

Methylprednisolone

Methylprednisolone Acetate

Methylprednisolone Hemisuccinate

Prednisolone acetate

Prednisolone hemisuccinate

Prednisolone phosphate

The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.

Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion.

Picoplatin

docetaxel

Robert Earhart, MD

This study will review the safety of picoplatin, a new type of platinum drug, with docetaxel, a drug commonly used in the treatment of prostate cancer. Patients who are eligible for this study will have had a diagnosis of hormone-refractory prostate cancer that has metastasized to other areas of the body, and have not been previously treated with chemotherapy drugs. Picoplatin will be administered in combination with docetaxel and prednisone to identify the maximum tolerated dose (MTD). Patients will receive IV treatments of picoplatin with docetaxel every 3 weeks, with prednisone, 5 mg orally, twice daily.

A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer

A Phase 1/2 Study of Picoplatin and Docetaxel (With Prednisone) in Subjects With Chemotherapy-Naive Metastatic Hormone-Refractory Prostate Cancer

Poniard Pharmaceuticals

Robert Earhart, MD, PhD

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.	NCT05624099	Esophageal Neop... Esophageal Dise... Digestive Syste...	camrelizumab Paclitaxel drug... Platinum drug Radiation	18 Years - 75 Years	Fujian Cancer Hospital
A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer	NCT00448734	Hormone Refract...	Picoplatin docetaxel	18 Years -	Poniard Pharmaceuticals
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.	NCT05624099	Esophageal Neop... Esophageal Dise... Digestive Syste...	camrelizumab Paclitaxel drug... Platinum drug Radiation	18 Years - 75 Years	Fujian Cancer Hospital

Spots Global Cancer Trial Database for platinum drug